- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Exact Sciences' Cologuard Receives CMS National Coverage
The non-invasive nature of the test makes it a very attractive alternative to the uncomfortable colonoscopy used to detect colorectal cancer. In a New England Journal of Medicine study of 10,000 patients, the test identified 92% of colorectal cancers in average-risk patients and 42% of polyps.
A new molecular diagnostic approved by Medicare and Medicaid is among the first non-invasive alternatives to colonoscopies, a potential boon for patients and payers but also a new piece of the personalization puzzle to manage.
Shares of Madison, Wisconsin-based Exact Sciences soared 36% on Friday, October 10th, after the biotech announced that its Cologuard stool-based colon cancer test received national coverage approval from CMS.
The at-home screening tool is the first Medicare-covered stool-based DNA test for detecting colon cancer and pre-colon cancer, approved once every 3 years for beneficiaries ages 50 to 85 who are asymptomatic and at average risk of the disease, with no family history or presence of inflammatory bowel diseases.
"Colorectal cancer is often considered the most preventable, yet least prevented cancer due to the lack of patient compliance with screening,” said Kevin Conroy, Exact Sciences president and CEO.
It is the second-leading cause of cancer deaths in the US but it does have a 90% 5-year survival rate when the disease is detected in early stages.
Read the article on Heathcare Payer News: http://bit.ly/1vvlvKA
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
